We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bio-Rad in HIV Licensing Deal with Calypte

By Labmedica staff writers
Posted on 18 Oct 2004
Print article
A worldwide nonexclusive licensing agreement for patents relating to the HIV-2 virus has been acquired by Calypte Biomedical (Pleasanton, CA, USA) from Bio-Rad Corp. (Hercules, CA, USA).

Bio-Rad is the exclusive licensee of the Institut Pasteur of Paris (France) under the HIV-2 patents. This license now allows Calypte's rapid HIV tests to diagnose a broader population of HIV-infected individuals. The company specializes in novel tests such as the HIV-1 Incidence enzyme immunoassay (EIA) and is developing new tests for the rapid detection of HIV and other sexually transmitted infectious diseases.

"This license will help us reach our goal of providing comprehensive HIV rapid tests that can test for various strains of the HIV virus on a wide array of specimen types, such as urine, oral fluid, blood, and plasma,” noted Dr. Richard George, president and CEO of Calypte. "This HIV-2 license is also intended to allow us to sell the test globally where the disease is not confined to the more prevalent HIV-1 strain.”

According to a report by the Global Business Coalition on HIV/AIDS, based on its estimates and that of the World Health Organization (WHO, Geneva, Switzerland), new infections are on the rise. Only 400,000 of the six million people in need of antiretroviral therapy have access to medicine. To meet the goal of WHO to test three million people by the end of 2005, 500,000 people will need to be tested each day.



Related Links:
Bio-Rad
Calypte
Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more